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Searching for Novel HIV-1 Reverse Transcriptase Inhibitors: a Relaxed
Complex Approach
Anthony Ivetac, J. Andrew McCammon.
University of California San Diego, La Jolla, CA, USA.
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/
AIDS) currently represents the fourth leading cause of death worldwide and
has claimed the lives of over 25 million people since 1981. To combat this in-
fectious disease, a wide range of drugs has been discovered, inhibiting various
stages of the retroviral life cycle. The most popular target is the HIV-1 reverse
transcriptase (RT) enzyme, which is required to convert retroviral RNA into
DNA, and for which substantial high-resolution structural data exist. Here,
we focus on the non-nucleoside RT inhibitor (NNRTI) class of compounds,
which confer high specificity and block DNA polymerization in an allosteric
fashion. Despite the FDA-approval of four NNRTIs to date, the side-effects
of drug toxicity and the emergence of drug-resistance mutations demand fur-
ther drug discovery endeavors. To this end, we have performed a virtual screen-
ing study of the RT enzyme, with the aim of discovering novel NNRTI lead
compounds from the National Cancer Institute (NCI) library. To take into ac-
count the conformational flexibility of the protein, we have screened mini-
libraries of NCI compounds against diverse ensembles of RT structures. Firstly,
we use a traditional, experimental source of structures: x-ray crystallography.
Next, in an effort to expose novel conformations of the binding site that might
be missed experimentally, we use a theoretical source: molecular dynamics
(MD) simulation. To achieve this, we have carried out all-atom, explicit solvent
MD simulation of the RT enzyme, complexed with a variety of NNRTIs. By
integrating the results from the crystallographic and MD ("relaxed") ensemble
screens, we compile a set of the most promising candidate compounds for
experimental testing.
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Recreating the Structure and Dynamics of Ancestral Proteins
Tyler Glembo, Michael Thorpe, S. Banu Ozkan.
Arizona State University, Tempe, AZ, USA.
Although protein structures are more evolutionarily conserved than protein se-
quences, the majority of work done in studying mutations in evolutionarily
diverged proteins is at the DNA sequence level. In this work, we use a combi-
nation of the Zipping Assembly Method of protein structure prediction (1) and
FRODA, a constrained geometric Monte Carlo simulation (2) used for explor-
ing conformational space, to reconstruct ancestral proteins. By using reservoir
Replica Exchange Molecular Dynamics we effectively both determine the
native like conformation and sample near native states (3). We then dock
the appropriate ligands to the predicted native ancestral structure and near
native conformations to compute both ligand binding affinity and also binding
poses. Initial results from simulations of ~440 million year old ancestral glu-
cocorticoid and corticoid steroid receptor proteins indicate that we are able to
fold these proteins to <3A˚ from native and that our calculated ligand binding
affinities agree with experimental results (4) from reconstructed ancestral pro-
teins. Furthermore, by examining the flexibility of ancestral proteins, we can
identify which mutations are most critical in shifting binding affinity from pro-
miscuous binding to highly specific binding of only a few ligands. This also
gives insight into the non-reversibility of evolution and into the design of
new molecules.
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Computational Methods for Mapping Ligand Induced Conformational
Changes in GPCRs
Supriyo Bhattacharya, Nagarajan Vaidehi.
City of Hope National Medical Center, Duarte, CA, USA.
The active conformation of a G-Protein Coupled Receptor (GPCR) is influ-
enced by the chemical structure and efficacy of the bound ligand. Insight
into the active conformation and activation pathway for ligands with different
efficacies is critical in designing functionally specific drugs for GPCRs. Using
the computational method LITiCon, we have predicted the activation pathways
for full, partial and inverse agonists of b2 Adrenergic Receptor, which are in
agreement with fluorescence intensity lifetime measurements. Starting fromthe inactive state, the full agonists take the receptor to a stable intermediate
in an energy downhill step (fast step), followed by a barrier crossing leading
to the active state (slow step). The reasons for the energy barrier are the disrup-
tion of a HB between N293 on TM6 and S204 on TM5 as well as the one
between D113 on TM3 and the b-hydroxyl group on the ligand. During MD
simulation of norepinephrine bound b2-AR, water polarization helps to disrupt
the HB between D113 and b-hydroxyl thus facilitating the barrier crossing. In
contrast with the full agonists, the activation pathway for the partial agonist
salbutamol involves only a slow step, which stems from steric interactions
between the ligand and the aromatic residues on TM6.
We have further refined the LITiCon method to optimize the backbone tilts and
kinks of the transmembrane helices in the presence of a bound ligand. We will
present the details of the method and the results on validation of rhodopsin
activation by all-trans retinal, and b2-AR bound to various agonists to investi-
gate the modulation of helical kinks and tilts due to agonist binding.
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Homology Modelling and Molecular Dynamics Simulations of the TAP
ABC Transporter
Valentina Corradi, Peter Tieleman.
University of Calgary, Calgary, AB, Canada.
ATP-Binding Cassette (ABC) transporters constitute one of the largest families
of membrane proteins. These proteins transport a variety of substrates and are
associated with a large number of diseases such as multi-drug resistance in can-
cer, diabetes, cystic fibrosis, and immune deficiencies. Several members of the
ABC super-family act as a pump to import or export molecules; others are lipid
flippases or regulatory subunits of potassium channels, and one member acts as
a chloride channel. Despite this functional diversity, ABC transporters share
a common mechanism of action, using energy derived from ATP hydrolysis
to allow the translocation of their substrates. The basic architecture consists
of two transmembrane domains (TMDs) coupled with two nucleotide binding
domains (NBDs), where the binding and the hydrolysis of ATP drives specific
conformational changes, in turn transmitted to TMDs to complete the transport
cycle. The transporter associated with antigen processing (TAP) is an ABC het-
erodimer (TAP1/TAP2) which translocates peptides into the ER for loading
them onto MHC class I molecules. Using the crystal structures of P-glycopro-
tein (1) in an inward-facing conformation and of Sav1866 in outward-facing
conformation (2), we built homology models of TAP corresponding to the ini-
tial and final stages of the transport cycle, respectively. We carried out molec-
ular dynamics simulations of these models to investigate the structural features
of the different conformational states of TAP, as a fundamental step to eluci-
date the mechanism of action of this transporter.
1) Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell,
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Gentaro Morimoto1, Ryoko Yanai1, Yosuske Ohno3, Tetsu Narumi4,
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Lead discovery is one of the most important processes in rational drug design.
To improve the rate of the detection of lead compounds, various technologies
such as high-throughput screening and combinatorial chemistry have been in-
troduced into the pharmaceutical industry. However, since these technologies
alone may not improve lead productivity, computational screening has become
important. A central method for computational screening is molecular docking.
This method generally docks many flexible ligands to a rigid protein and pre-
dicts the binding affinity for each ligand in a practical time. However, its ability
to detect lead compounds is less reliable. In contrast, molecular dynamics sim-
ulations can treat both proteins and ligands in a flexible manner, directly esti-
mate the effect of explicit water molecules, and provide more accurate binding
affinity, although their computational cost and time are significantly greater
than those of molecular docking. Therefore, we developed a special purpose
computer "MDGRAPE-3" for molecular dynamics simulations and applied it
to computational screening. In this paper, we report an effective method for
computational screening; this method is a combination of molecular docking
and massive-scale molecular dynamics simulations. The proposed method
showed a higher and more stable enrichment performance than the molecular
docking method used alone.
